Announcements and Notices - [Other - Business Update]

Jacobio Pharmaceuticals Co. Ltd. operates as a biotech company. The Company develops and sells cancer innovative drugs, autoimmune drugs, infectious diseases drugs, and other products. Jacobio Pharmaceuticals markets its products throughout China.

Voluntary Announcement
The Registrational Clinical Data Of Kras Inhibitor
Glecirasib Was Published In The Medical
Journal Nature Medicine

Voluntary Announcement
Jacobio Presented The Preliminary Clinical Data Of Bet
Inhibitor Jab-8263 To Treat Myelofibrosis At The 2024 66th
American Society Of Hematology Annual Meeting

Voluntary Announcement 
Jacobio Completed First Patient Dosage In The Phase I/Iia Clinical Trial Of Pan-Kras Inhibitor Jab-23e73 In China

Next Day Disclosure Returns - [Share Buyback]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Voluntary Announcement The Registrational Clinical Data Of Kras Inhibitor Glecirasib Was Published In The Medical Journal Nature Medicine

Voluntary Announcement Jacobio Presented The Preliminary Clinical Data Of Bet Inhibitor Jab-8263 To Treat Myelofibrosis At The 2024 66th American Society Of Hematology Annual Meeting

Voluntary Announcement Jacobio Completed First Patient Dosage In The Phase I/Iia Clinical Trial Of Pan-Kras Inhibitor Jab-23e73 In China

Next Day Disclosure Return

Next Day Disclosure Return